Research Papers:

Association of vitamin D receptor Fok I polymorphism with the risk of prostate cancer: a meta-analysis

Shaosan Kang _, Yansheng Zhao, Jian Liu, Lei Wang, Geng Zhao, Xi Chen, Anliang Yao, Liguo Zhang, Xiaojun Zhang and Xiaoqiang Li

PDF  |  HTML  |  How to cite

Oncotarget. 2016; 7:77878-77889. https://doi.org/10.18632/oncotarget.12837

Metrics: PDF 1594 views  |   HTML 2204 views  |   ?  


Shaosan Kang1, Yansheng Zhao2, Jian Liu1, Lei Wang1, Geng Zhao3, Xi Chen1, Anliang Yao1, Liguo Zhang1, Xiaojun Zhang1, Xiaoqiang Li1

1Department of Urology, North China University of Science and Technology Affiliated Hospital, Tangshan 063000, China

2Department of Imaging, KaiLuan General Hosptial, Tangshan 063000, China

3Department of Urology, KaiLuan General Hospital, Tangshan 063000, China

Correspondence to:

Shaosan Kang, email: [email protected]

Keywords: Fok I, prostate cancer, vitamin D receptor, polymorphisms, meta-analysis

Received: June 13, 2016     Accepted: October 13, 2016     Published: October 24, 2016


Several previous studies have been reported to examine the association between Vitamin D receptor (VDR) gene Fok I polymorphism and susceptibility to prostate cancer (PCa), however the results remain inconclusive. To provide a relatively comprehensive account of the association, we searched PubMed, Embase, CNKI, and Wanfang for eligible studies and carry out this meta-analysis. A total of 27 case-control studies with 10,486 cases and 10,400 controls were included. In the overall analysis, Fok I polymorphism was not significantly associated with the susceptibility to PCa. Subgroup analyses showed that significantly association was existed in Caucasian population, the subgroup of population-based controls and the stratified group with advanced tumor.These results indicate that the VDR Fok I polymorphism might be capable of causing PCa susceptibility and could be a promising target to forecast the PCa risk for clinical practice. However further well-designed epidemiologic studies are needed to confirm this conclusion.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 12837